Dr Katy Taylor, director of Science and Regulatory Affairs at Cruelty Free International discusses the use of dogs within toxicology assessments and why change is needed.
In this episode we speak to Professor David Nutt about his recent decision to join the biotech Awakn Life Sciences to help the company bring about a change to mental health treatments through the use of psychedelic medicines.
Tim Gardner, director of Manufacturing & NPI at Vectura explores the considerations to make when manufacturing formulations for dry powder inhaled products.
Robert Hewitt founder of Biosample Hub looks at the problems biotechs have in accessing samples within NHS biobanks and what can be done to improve collaboration between the NHS and industry.
Professor Saad Shakir, director of the Drug Safety Research Unit looks at observational research in the UK and why it's one of the nation's core strengths.
Roy Butcher, procurement manager at Southgate Packaging looks at the latest trends in anti-counterfeiting packaging technologies and how Covid-19 has played a major role in product innovation.
Adrienne Rivlin, Partner, and Jess Sharpe, Associate, at L.E.K. Consulting assess the rise in investment seen within the psychedelics market for mental health.
Sue Ellison, joint MD of OPM (labels and packaging) Group looks at how counterfeiting measures for pharmaceuticals packaging are being affected in a post-Brexit world.
Dr Ash Ramzan, founder and principal consultant at regulatory affairs consultancy, Woodley BioReg looks at how the key requirements of the Falsified Medicines Directive are being fulfilled by stakeholders and manufacturers.
Pedro Lichtinger, CEO and chairman of biotech Starton Therapeutics, speaks to EPM about the company’s mission to improve cancer care using transdermal technology.
